{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:42:59Z","timestamp":1776152579998,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Apixaban is a direct-acting oral anticoagulant that selectively inhibits factor Xa. Reversal strategies utilized to treat factor Xa inhibitor\u2013associated bleeding include andexanet alfa, prothrombin complex \u00adconcentrate (PCC), and activated PCC (aPCC). The optimal treatment of traumatic intracranial hemorrhage in the setting of an apixaban overdose is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>This case report describes a 69-year-old female who initially presented to an emergency department at a community hospital due to a ground-level fall with traumatic intracranial hemorrhage. The patient reportedly ingested apixaban 275 mg, carvedilol 250 mg, atorvastatin 1,200 mg, and unknown amounts of amlodipine and ethanol. Anti-inhibitor coagulant complex, an aPCC, was administered approximately 3 hours after presentation. Initial thromboelastography performed approximately 4 hours after presentation showed a prolonged reaction time of 16.8 minutes. Ongoing imaging and evidence of coagulopathy prompted repeated aPCC administration to a cumulative dose of approximately 100 U\/kg. The patient underwent craniotomy with hematoma evacuation. Postoperative imaging showed expansion of the existing intracranial hemorrhage and new areas of hemorrhage. Andexanet alfa was administered approximately 18 hours after presentation, followed by repeat craniotomy with evacuation of the hematoma. No further expansion of the intracranial hemorrhage was observed, and the reaction time on thromboelastography was normalized at 6.3 minutes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This case suggests that andexanet alfa may have a role in the management of traumatic hemorrhage in the setting of an acute massive apixaban overdose. Use of andexanet alfa, PCC, and aPCC in this context requires further research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad215","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:54:05Z","timestamp":1694188445000},"page":"1722-1728","source":"Crossref","is-referenced-by-count":4,"title":["Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report"],"prefix":"10.1093","volume":"80","author":[{"given":"Daniel","family":"Jenniches","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Allegheny Health Network , Pittsburgh, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail F","family":"Kerns","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Allegheny Health Network , Pittsburgh, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"DelBianco","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Allegheny Health Network , Pittsburgh, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P","family":"Stripp","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Allegheny Health Network , Pittsburgh, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan S","family":"Philp","sequence":"additional","affiliation":[{"name":"Department of Trauma and Acute Care Surgery, Allegheny Health Network , Pittsburgh, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,9]]},"reference":[{"key":"2023112211415961400_CIT0001","author":"Eliquis (apixaban)","year":"2021"},{"issue":"5","key":"2023112211415961400_CIT0002","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023112211415961400_CIT0003","author":"Kcentra (prothrombin complex concentrate [human])","year":"2020"},{"key":"2023112211415961400_CIT0004","author":"FEIBA","year":"2020"},{"issue":"1","key":"2023112211415961400_CIT0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/rth2.12015","article-title":"The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro","volume":"1","author":"Schultz","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"2023112211415961400_CIT0006","author":"Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo)","year":"2022"},{"issue":"5","key":"2023112211415961400_CIT0007","doi-asserted-by":"crossref","first-page":"e12775","DOI":"10.1002\/rth2.12775","article-title":"In vitro reversal of direct factor Xa inhibitors: direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex\/Kcentra","volume":"6","author":"Brinkman","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"2023112211415961400_CIT0008","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/rth2.12418","article-title":"Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation","volume":"4","author":"Lu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"25","key":"2023112211415961400_CIT0009","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2023112211415961400_CIT0010","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2023112211415961400_CIT0011","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1097\/CCM.0000000000005059","article-title":"Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis","volume":"49","author":"Nederpelt","year":"2021","journal-title":"Crit Care Med"},{"issue":"2","key":"2023112211415961400_CIT0012","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"2023112211415961400_CIT0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2018.11.009","article-title":"Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants","volume":"173","author":"Dager","year":"2019","journal-title":"Thromb Res"},{"issue":"3","key":"2023112211415961400_CIT0014","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12028-015-0213-y","article-title":"The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage","volume":"24","author":"Dibu","year":"2016","journal-title":"Neurocrit Care"},{"issue":"2","key":"2023112211415961400_CIT0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajem.2018.05.023","article-title":"Safety and effectiveness of factor VIII inhibitor bypassing activity for direct oral anticoagulant-related hemorrhage reversal","volume":"37","author":"Engelbart","year":"2019","journal-title":"Am J Emerg Med"},{"issue":"12","key":"2023112211415961400_CIT0016","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/10600280211004583","article-title":"Factor VIII inhibitor bypassing activity (FEIBA) reversal for apixaban and rivaroxaban in patients with acute intracranial and nonintracranial hemorrhage","volume":"55","author":"Hunt","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2023112211415961400_CIT0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12028-017-0383-x","article-title":"Safety and effectiveness of factor VIII inhibitor bypassing activity (FEIBA) and fresh frozen plasma in oral anticoagulant-associated intracranial hemorrhage: a retrospective analysis","volume":"27","author":"Yin","year":"2017","journal-title":"Neurocrit Care"},{"key":"2023112211415961400_CIT0018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2021.08.005","article-title":"Activated prothrombin complex concentrate for reversal of oral factor Xa inhibitors at a level 1 trauma center","volume":"206","author":"Bobby","year":"2021","journal-title":"Thromb Res"},{"issue":"9","key":"2023112211415961400_CIT0019","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/15563650.2016.1204453","article-title":"Anti-Xa activity in apixaban overdose: a case report","volume":"54","author":"Barton","year":"2016","journal-title":"Clin Toxicol"},{"issue":"1","key":"2023112211415961400_CIT0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bcp.13790","article-title":"Self-poisoning with 60 tablets of apixaban, a pharmacokinetics case report","volume":"85","author":"Franck","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2023112211415961400_CIT0021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/MBC.0000000000000706","article-title":"Coagulation assays in a case of apixaban overdose","volume":"29","author":"Guadarrama","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2023112211415961400_CIT0022","doi-asserted-by":"crossref","first-page":"801.e5","DOI":"10.1016\/j.ajem.2016.11.035","article-title":"The X factor: lack of bleeding after an acute apixaban overdose","volume":"35","author":"Leikin","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"11","key":"2023112211415961400_CIT0023","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1160\/TH17-07-0474","article-title":"Apixaban auto-intoxication: toxicokinetics and coagulation tests","volume":"117","author":"Mast","year":"2017","journal-title":"Thromb Haemost"},{"issue":"5","key":"2023112211415961400_CIT0024","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ajem.2017.09.035","article-title":"Massive apixaban overdose\u2014a comparison of three cases","volume":"36","author":"Ilicki","year":"2018","journal-title":"Am J Emerg Med"},{"issue":"3","key":"2023112211415961400_CIT0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"issue":"16","key":"2023112211415961400_CIT0026","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/ajhp\/zxac079","article-title":"Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: case series","volume":"79","author":"Liu","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"2023112211415961400_CIT0027","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ajem.2016.12.061","article-title":"Thromboelastogram does not detect pre-injury anticoagulation in acute trauma patients","volume":"35","author":"Ali","year":"2017","journal-title":"Am J Emerg Med"},{"key":"2023112211415961400_CIT0028","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ajem.2021.12.011","article-title":"Evaluation of direct oral anticoagulant use on thromboelastography in an emergency department population","volume":"52","author":"Jenrette","year":"2022","journal-title":"Am J Emerg Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad215\/51770385\/zxad215.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/23\/1722\/53678042\/zxad215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/23\/1722\/53678042\/zxad215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:25:46Z","timestamp":1700673946000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/23\/1722\/7264887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,9]]},"references-count":28,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,9,9]]},"published-print":{"date-parts":[[2023,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad215","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,9,9]]}}}